ATAI
Atai Beckley N.V NASDAQ Listed Jun 18, 2021$4.05
Pre-mkt
$3.98
-1.63%
Mkt Cap $917.5M
52w Low $2.02
45.8% of range
52w High $6.45
50d MA $4.19
200d MA $4.29
P/E (TTM)
-1.4x
EV/EBITDA
—
P/B
4.1x
Debt/Equity
0.0x
ROE
-297.5%
P/FCF
-8.9x
RSI (14)
28.70
ATR (14)
$0.31
Beta
1.57
50d MA
$4.19
200d MA
$4.29
Avg Volume
5.1M
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Prof. J.H. Bavincklaan 7 · Amstelveen, NY 1183 AT · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6, 2026 | AMC | -0.12 | -0.05 | +58.3% | 3.39 | +0.3% | +14.7% | +6.4% | -1.9% | -5.9% | -3.4% | — |
| Nov 12, 2025 | AMC | -0.12 | -0.28 | -133.3% | 4.33 | -1.4% | -4.6% | -3.1% | -1.0% | -0.8% | -2.8% | — |
| Aug 14, 2025 | AMC | -0.12 | -0.14 | -16.7% | 4.01 | -1.5% | -3.2% | +4.4% | -2.0% | +0.0% | +10.6% | — |
| May 14, 2025 | AMC | -0.19 | -0.15 | +21.1% | 1.43 | +0.0% | +14.0% | +1.2% | +11.5% | +11.4% | -6.8% | — |
| Mar 17, 2025 | AMC | -0.14 | -0.24 | -71.4% | 1.46 | -2.7% | -7.5% | +3.0% | -1.4% | +5.8% | +8.3% | — |
| Nov 13, 2024 | AMC | -0.15 | -0.16 | -6.7% | 1.35 | +3.0% | +1.5% | +17.5% | +3.7% | +3.6% | -8.1% | — |
| Aug 13, 2024 | AMC | -0.17 | -0.36 | -111.8% | 1.22 | +0.0% | -4.1% | +6.8% | -2.4% | +7.4% | +0.0% | — |
| May 15, 2024 | AMC | -0.20 | -0.17 | +15.0% | 2.05 | +0.5% | -9.3% | -8.1% | +1.2% | -2.9% | -0.6% | — |
| Mar 28, 2024 | AMC | -0.17 | -0.12 | +29.4% | 1.97 | +0.0% | -5.6% | +0.5% | +27.8% | +5.0% | -2.4% | — |
| Nov 14, 2023 | AMC | -0.20 | -0.14 | +30.0% | 1.25 | +2.0% | -4.4% | -7.5% | +0.0% | +0.9% | -4.5% | — |
| Aug 10, 2023 | AMC | -0.21 | -0.21 | +0.0% | 1.71 | +0.6% | -1.8% | -1.2% | -3.0% | +3.7% | -4.8% | — |
| May 11, 2023 | AMC | -0.22 | -0.21 | +4.5% | 1.96 | +1.0% | -3.1% | +5.3% | -3.0% | -2.1% | -2.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.03 | $5.03 | +24.8% | +21.6% | -0.6% | -3.3% | +1.3% | -2.9% |
| Apr 17 | Guggenheim | Maintains | Buy → Buy | — | $4.09 | $4.19 | +2.4% | -1.5% | +21.6% | -0.6% | -3.3% | +1.3% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.65 | $3.70 | +1.4% | +0.0% | -2.5% | +0.3% | -2.2% | -2.9% |
| Mar 9 | Needham | Maintains | Buy → Buy | — | $3.39 | $3.40 | +0.3% | +14.7% | +6.4% | -1.9% | -5.9% | -3.4% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.63 | $3.50 | -3.6% | +1.4% | +0.3% | +0.0% | -4.1% | -4.2% |
| Oct 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.87 | $5.95 | +1.4% | -3.9% | -1.6% | +4.0% | +7.8% | -4.2% |
| Sep 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.88 | $5.11 | +4.7% | +15.0% | -2.1% | -5.8% | +1.9% | +3.4% |
| Jul 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.31 | $3.39 | +2.4% | +4.8% | +18.2% | +1.7% | +2.2% | -2.8% |
| Jul 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $3.57 | $3.13 | -12.3% | -6.7% | -0.6% | +4.8% | +18.2% | +1.7% |
| Jul 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $2.71 | $2.96 | +9.2% | +1.5% | +0.7% | -0.7% | -4.4% | +1.1% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.84 | $1.83 | -0.5% | +11.4% | -6.8% | +5.8% | +2.0% | +7.3% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.35 | $1.36 | +0.7% | +3.0% | -1.4% | +5.8% | +8.3% | +0.0% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.28 | -10.6% | -11.0% | +1.3% | -10.0% | +1.0% | -2.4% |
| Nov 18 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.61 | $1.65 | +2.5% | +3.7% | +3.6% | -8.1% | -4.4% | +5.9% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.61 | $1.65 | +2.5% | +3.7% | +3.6% | -8.1% | -4.4% | +5.9% |
No insider trades available.
8-K · 7.01
! Medium
Atai Beckley N.V -- 8-K 7.01: Regulation FD Disclosure
Jun 3
8-K · 2.02
!! High
Atai Beckley N.V -- 8-K 2.02: Earnings Results
May 12
8-K · 1.01
! Medium
AtaiBeckley Inc. -- 8-K 1.01: Equity Issuance
Atai Beckley Inc. (ATAI) established an open market sale agreement with Jefferies LLC, enabling the company to conduct at-the-market equity offerings for capital raising purposes.
Mar 9
8-K · 7.01
! Medium
AtaiBeckley Inc. -- 8-K 7.01: Regulation FD Disclosure
ATAI is hosting a virtual investor day on March 6, 2026, featuring executive presentations and Q&A sessions with KOLs to discuss company strategy and outlook.
Mar 6
8-K · 8.01
!! High
AtaiBeckley Inc. -- 8-K 8.01: Material Event / Announcement
ATAI completed its acquisition of the remaining stake in Beckley Psytech, consolidating full ownership of the psychedelic research company and strengthening its portfolio of mental health therapeutics.
Mar 6
8-K · 7.01
! Medium
AtaiBeckley Inc. -- 8-K 7.01: Regulation FD Disclosure
AtaiBeckley announced positive Phase 2a results for EMP-01, an oral MDMA treatment for social anxiety disorder, potentially validating its psychedelic therapeutic development pipeline.
Feb 26
8-K · 5.02
!!! Very High
AtaiBeckley Inc. -- 8-K 5.02: Executive Change
AtaiBiomedicines appointed Michael Faerm as CFO and principal accounting officer, strengthening financial leadership amid the company's clinical development programs.
Feb 19
Institutional (13F) — Top 17
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 9,641,946 | $39M | — | Dec 2025 |
| 2 | Jane Street Group, Llc | 759,996 | $3M | Added | Dec 2025 |
| 3 | Brown University | 718,500 | $3M | — | Mar 2026 |
| 4 | Stableford Capital Ii Llc | 286,282 | $1M | Reduced | Mar 2026 |
| 5 | Iq Eq Fund Management (Ireland) Ltd | 121,429 | $497K | Added | Dec 2025 |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 84,244 | $345K | New | Dec 2025 |
| 7 | Wealth Enhancement Advisory Services, Llc | 57,232 | $229K | Reduced | Dec 2025 |
| 8 | Cresset Asset Management, Llc | 35,984 | $190K | — | Sep 2025 |
| 9 | Zurcher Kantonalbank (Zurich Cantonalbank) | 46,375 | $190K | New | Dec 2025 |
| 10 | Robertson Stephens Wealth Management, Llc | 28,297 | $116K | Added | Dec 2025 |
| 11 | Pictet Asset Management Holding Sa | 22,253 | $91K | New | Dec 2025 |
| 12 | Verdence Capital Advisors Llc | 19,178 | $78K | — | Dec 2025 |
| 13 | Truist Financial Corp | 16,394 | $67K | — | Dec 2025 |
| 14 | Citigroup Inc | 11,071 | $45K | Reduced | Dec 2025 |
| 15 | Crewe Advisors Llc | 5,540 | $23K | — | Dec 2025 |
| 16 | Northwestern Mutual Wealth Management Co | 300 | $1K | New | Dec 2025 |
| 17 | Global Frontier Investments Llc | — | — | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 5
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | ARK Genomic Revolution ETF | 3,299,659 | $12M | Jan 2026 |
| 2 | AdvisorShares Psychedelics ETF | 567,587 | $2M | Mar 2026 |
| 3 | Virtus LifeSci Biotech Clinical Trials ETF | 65,670 | $247K | Jan 2026 |
| 4 | iShares Morningstar Small-Cap ETF | 12,738 | $48K | Jan 2026 |
| 5 | Avantis U.S. Equity ETF | 6,554 | $24K | Feb 2026 |
Valuation
Market Cap
$917.5M
Enterprise Value
$661.4M
P/E (TTM)
-1.35x
Forward P/E
—
PEG Ratio
-0.01x
P/B
4.13x
P/S
263.03x
P/FCF
-8.86x
EV/EBITDA
—
Shares Out
226.5M
Financials (TTM)
Revenue
$3.5M
Net Income
-$663.4M
EBITDA
-$662.5M
Free Cash Flow
-$103.6M
Op Cash Flow
-$102.7M
EPS Basic
$-2.91
EPS Diluted
$-3.00
EPS Forward
$-0.48
Gross Margin
82.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$310.5M
Total Liab.
$88.5M
Total Equity
$222.0M
Cash
$256.0M
LT Debt
$0
Book Value/Sh
$0.98
Debt/Equity
0.01x
Current Ratio
11.74
Quick Ratio
11.74
Returns & Growth
ROE
-297.5%
ROA
-225.5%
ROIC
-39.7%
Rev Growth YoY
+1227.6%
EPS Growth YoY
-212.9%
Price Returns
2W
+12.1%
1M
+8.9%
3M
+24.8%
6M
+16.5%
12M
+96.1%
Technicals
52W High
$6.45
52W Low
$2.02
50d MA
$4.19
200d MA
$4.29
RSI (14)
28.70
ATR (14)
$0.31
Beta
1.57
Avg Volume
5.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.00
High
$15.00
Low
$10.00
Median
$11.50
Data updated apr 24, 2026 7:26pm
· Source: financialmodelingprep.com